Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 1/2004

01-07-2004

Existence of Leukemic Clones Resistant to Both Imatinib Mesylate and Rituximab before Drug Therapies in a Patient with Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Authors: Takaaki Hato, Jun Yamanouchi, Tatsushiro Tamura, Norimasa Hojo, Yasunari Niiya, Masashi Kohno, Shiro Bando, Yoshihiro Yakushijin, Kiyonori Takada, Ikuya Sakai, Masaki Yasukawa, Shigeru Fujita

Published in: International Journal of Hematology | Issue 1/2004

Login to get access
Metadata
Title
Existence of Leukemic Clones Resistant to Both Imatinib Mesylate and Rituximab before Drug Therapies in a Patient with Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Authors
Takaaki Hato
Jun Yamanouchi
Tatsushiro Tamura
Norimasa Hojo
Yasunari Niiya
Masashi Kohno
Shiro Bando
Yoshihiro Yakushijin
Kiyonori Takada
Ikuya Sakai
Masaki Yasukawa
Shigeru Fujita
Publication date
01-07-2004
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2004
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.04033

Other articles of this Issue 1/2004

International Journal of Hematology 1/2004 Go to the issue

OriginalPaper

Angiopoietin-Related/Angiopoietin-Like Proteins Regulate Angiogenesis

Case Report

Exaggerated Cutaneous Response to Mosquito Bites in a Patient with Chronic Lymphocytic Leukemia

OriginalPaper

Unmanipulated HLA-Haploidentical Bone Marrow Transplantation for the Treatment of Fatal, Nonmalignant Diseases in Children and Adolescents

OriginalPaper

Differentiation and Diversification of Vascular Cells from Embryonic Stem Cells

OriginalPaper

Molecular Mechanisms of Lymphangiogenesis

OriginalPaper

Two Entities of Precursor T-Cell Lymphoblastic Leukemia/Lymphoma Based on Radiologic and Immunophenotypic Findings
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits